The cancer anorexia/weight loss syndrome: Therapeutic challenges
- 69 Downloads
The cancer anorexia/weight loss syndrome is characterized by loss of weight, loss of appetite, overall decline in quality of life, and shortened survival in patients with advanced incurable cancer. It is highly prevalent. To date, treatment options that have been firmly established with good scientific evidence are limited to progestational agents and corticosteroids, both of which have been demonstrated to improve appetite but have otherwise failed to have a favorable impact on some of the other aspects of this syndrome. As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge.
Unable to display preview. Download preview PDF.
- 9.Cohn SH, Gartenhaus W, Sawitsky A, et al.: Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabol Clin Exp 1981, 30:222–229.Google Scholar
- 10.Kotler DP, Tierney AR, Wang J, Pierson RN: Magnitude of body cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutrition 1989, 50:444–7.Google Scholar
- 11.Keys A, Brozek J, Henschel A, et al.: The Biology of Human Starvation. St. Paul, MN: The University of Minnesota Press, 1950.Google Scholar
- 15.Bossola M, Muscaritoli M, Costelli P, et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003, 237:384–389. This paper provides some of the first data on the ubiquitin-proteasome pathway in the clinical setting.PubMedCrossRefGoogle Scholar
- 16.Jatoi A, Alberts S, Foster N, et al.: Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer, in press.Google Scholar
- 19.Torelli GF, Meguid MM, Moldawer LL, et al.: Use of recombinant soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol 1999, 277 (3 Pt 2):R850-R855. This paper provides some of the most compelling preclinical data on the need to pursue clinical investigation of TNF blockade for the cancer anorexia/weight loss syndrome.PubMedGoogle Scholar